Brought to you by 
AC Immune, Janssen collaborate on AD and tauopathy vaccines
01 Feb 2023
Executive Summary
AC Immune SA licensed Janssen Pharmaceuticals Inc. exclusive worldwide rights to its Phase Ib tau-targeted vaccine ACI35 for Alzheimer’s disease. The companies concurrently agreed to a three-year collaboration to research treatments for other tauopathies, which like AD are characterized by prominent filamentous tau lesions. These diseases include frontotemporal dementia, progressive supranuclear palsy, and amyotrophic lateral sclerosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AC Immune, Janssen collaborate on AD and tauopathy vaccines
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice